KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Common Equity (2016 - 2025)

Novavax has reported Common Equity over the past 16 years, most recently at -$127.8 million for Q4 2025.

  • Quarterly results put Common Equity at -$127.8 million for Q4 2025, up 79.52% from a year ago — trailing twelve months through Dec 2025 was -$127.8 million (up 79.52% YoY), and the annual figure for FY2025 was -$127.8 million, up 79.52%.
  • Common Equity for Q4 2025 was -$127.8 million at Novavax, up from -$156.7 million in the prior quarter.
  • Over the last five years, Common Equity for NVAX hit a ceiling of $1.0 billion in Q1 2021 and a floor of -$895.6 million in Q1 2023.
  • Median Common Equity over the past 5 years was -$424.3 million (2022), compared with a mean of -$273.7 million.
  • Biggest five-year swings in Common Equity: skyrocketed 4434.93% in 2021 and later plummeted 1470.98% in 2023.
  • Novavax's Common Equity stood at -$351.7 million in 2021, then plummeted by 80.3% to -$634.1 million in 2022, then fell by 13.07% to -$716.9 million in 2023, then rose by 12.98% to -$623.8 million in 2024, then skyrocketed by 79.52% to -$127.8 million in 2025.
  • The last three reported values for Common Equity were -$127.8 million (Q4 2025), -$156.7 million (Q3 2025), and $37.6 million (Q2 2025) per Business Quant data.